newsfilter
← Latest News
GlobeNewswire·

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE,